全文获取类型
收费全文 | 3494篇 |
免费 | 275篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 170篇 |
妇产科学 | 55篇 |
基础医学 | 391篇 |
口腔科学 | 119篇 |
临床医学 | 423篇 |
内科学 | 998篇 |
皮肤病学 | 38篇 |
神经病学 | 217篇 |
特种医学 | 307篇 |
外科学 | 396篇 |
综合类 | 45篇 |
预防医学 | 247篇 |
眼科学 | 28篇 |
药学 | 177篇 |
中国医学 | 8篇 |
肿瘤学 | 185篇 |
出版年
2023年 | 18篇 |
2022年 | 31篇 |
2021年 | 79篇 |
2020年 | 45篇 |
2019年 | 84篇 |
2018年 | 99篇 |
2017年 | 61篇 |
2016年 | 64篇 |
2015年 | 77篇 |
2014年 | 119篇 |
2013年 | 152篇 |
2012年 | 197篇 |
2011年 | 234篇 |
2010年 | 152篇 |
2009年 | 127篇 |
2008年 | 187篇 |
2007年 | 227篇 |
2006年 | 177篇 |
2005年 | 174篇 |
2004年 | 151篇 |
2003年 | 141篇 |
2002年 | 141篇 |
2001年 | 38篇 |
2000年 | 23篇 |
1999年 | 33篇 |
1998年 | 91篇 |
1997年 | 105篇 |
1996年 | 96篇 |
1995年 | 56篇 |
1994年 | 47篇 |
1993年 | 57篇 |
1992年 | 30篇 |
1991年 | 20篇 |
1990年 | 29篇 |
1989年 | 47篇 |
1988年 | 46篇 |
1987年 | 41篇 |
1986年 | 44篇 |
1985年 | 39篇 |
1984年 | 17篇 |
1983年 | 20篇 |
1982年 | 24篇 |
1981年 | 19篇 |
1980年 | 26篇 |
1979年 | 11篇 |
1978年 | 12篇 |
1977年 | 17篇 |
1976年 | 16篇 |
1975年 | 14篇 |
1968年 | 6篇 |
排序方式: 共有3815条查询结果,搜索用时 31 毫秒
81.
The medical management of heart failure has undergone remarkable progress in the past 10 years. The paradigm shift is toward long-term reparative strategies that help in altering the biologic properties of the failing heart. Together with angiotensin-converting enzyme inhibitors, beta blockers have emerged as standard therapy for heart failure, especially for patients with mild to moderate heart failure. Since most of the clinical trials demonstrating the benefits of betablockers have been done in patients with mild to moderate heart failure, some controversy exists about the utility of beta-blocking agents in patients with advanced heart failure. This review will summarize the rationale and the use of beta blockers, a very challenging therapeutic strategy, in patients with severe heart failure. 相似文献
82.
Die Innere Medizin - Die hausarztzentrierte Versorgung (HZV) wurde auf Grundlage der GKV-Modernisierungsgesetze (GKV gesetzliche Krankenversicherung) von 2004 und 2007 in die ambulante Versorgung... 相似文献
83.
Extended follow‐up of pediatric liver transplantation patients receiving once daily calcineurin inhibitor
下载免费PDF全文
![点击此处可从《Pediatric transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Henry C. Lin Hector Melin‐Aldana Saeed Mohammad Udeme D. Ekong Estella M. Alonso 《Pediatric transplantation》2015,19(7):709-715
We describe longitudinal results in a cohort of pediatric liver transplant patients successfully minimized to once daily CNI monotherapy for longer than five yr and assess changes in liver biochemistries and liver histology. A retrospective chart review of all pediatric liver transplant patients at a single center was performed. Biopsies and serum biochemistries (AST, ALT, total bilirubin, direct bilirubin, INR, creatinine) are reported at time points: PM, five‐yr, seven‐yr, and nine‐yr post‐minimization. Biopsies were assessed for inflammation and fibrosis using Ishak and Batts grading systems. Successful minimization to daily CNI monotherapy was defined as normal liver enzymes with no episodes of rejection. Thirty‐three patients have successfully remained on once daily CNI for >5 yr, and 19/33 of these patients have serial liver biopsies available for review. We report on the clinical and histological findings of these 19 patients. All 19 patients continue to have normal liver biochemistries. On post‐minimization biopsies, fibrosis progressed by ≥2 stages in one patient (5.3%) despite normal liver biochemistries. Carefully selected patients can tolerate minimization to once daily CNI monotherapy as few have progression of fibrosis. 相似文献
84.
Primary cardiac lymphoma is defined as a lymphoma of the heart and pericardium with little or no extracardiac or local involvement such as mediastinal lymph nodes or pleural effusion. Most cases are diagnosed only post mortem (1). If this disease could be diagnosed earlier, therapy with chlorpropamide, doxorubicin, vincristine and prednisone (CHOP) could bring about a remission (2,3,4). Transoesophageal echocardiography with three-dimensional acquisition is a new technique which can allow earlier diagnosis, and facilitate guided transvenous biopsy (5,6). We here report an example of the pre-mortem diagnosis of cardiac lymphoma by these techniques. 相似文献
85.
M. S. Collins R. F. Hector R. E. Roby A. A. Edwards D. K. Ladehoff J. H. Dorsey 《Infection》1987,15(2):S51-S59
86.
Ventura HO 《The American journal of cardiology》2004,93(4):516-517
During my medical school years, I became acquainted with Dr. Guyton's physiology textbook. This book was very instrumental in shaping my future career in cardiovascular medicine. 相似文献
87.
Interleukin-1 alpha (IL-1 alpha) is a macrophage-derived, multifunctional cytokine that broadly potentiates myelopoiesis and induces the synthesis of hematopoietic colony-stimulating factors (CSF) in vitro and in vivo. To evaluate the possibility for use of IL-1 alpha in ameliorating in vivo bone marrow suppression induced by drugs or radiation, we examined the in vivo effects of the cytokine on erythropoietic and other hematopoietic progenitor cells. Normal mice were treated with a single intraperitoneal (IP) injection of recombinant human IL-1 alpha at varying doses and were assayed at various times post-treatment. By six hours postinjection, a significant suppression of mature erythroid progenitors (CFU-E) was observed in animals treated with IL-1 alpha (0.5 micrograms/mouse), with maximum suppression of CFU-E and peripheral blood reticulocyte counts occurring at 24 hours. Decreases in peripheral blood hematocrit did not occur after a single IL-1 alpha injection but were observed after multiple injections of the cytokine. The suppressive effects of IL-1 alpha on late-stage erythropoiesis were abrogated by simultaneous administration of erythropoietin (EPO). At 48 hours post-treatment, a marked stimulation was observed in the numbers of spleen and marrow immature erythroid (BFU-E), macrophage (CFU-M), granulocyte (CFU-G), granulocyte- macrophage (CFU-GM), and megakaryocyte (CFU-meg) progenitor cells. These results demonstrate the potential use of IL-1 alpha as a generalized stimulator of hematopoiesis and show that the cytokine- induced suppression of late-stage erythropoiesis can be prevented by EPO. 相似文献
88.
Maciej Cabanski Brett Fields Stephanie Boue Natalia Boukharov Hector DeLeon Natalie Dror Marcel Geertz Emmanuel Guedj Anita Iskandar Ulrike Kogel Celine Merg Michael J. Peck Carine Poussin Walter K. Schlage Marja Talikka Nikolai V. Ivanov Julia Hoeng Manuel C. Peitsch 《Inflammation research》2015,64(7):471-486
89.
90.
Kayode O. Kuku Hector M. Garcia-Garcia Edward Koifman Alexandre H. Kajita Sameer Desale Viana Azizi Gebremedhin Melaku Anh Bui Yael F. Meirovich Solomon Beyene Aaphtaab Dheendsa Blaine Schneider Ron Waksman On behalf of the CELLO study investigators 《The international journal of cardiovascular imaging》2018,34(3):345-352
The CliRpath Excimer Laser System to Enlarge Lumen Openings (CELLO) registry included patients treated with modified excimer laser catheters for the endovascular treatment of peripheral artery disease affecting the superficial femoral artery (SFA) and proximal popliteal artery. The aim of this study was to assess, via intravascular ultrasound (IVUS) the dissections in the vessel wall following treatment with the laser catheters. IVUS grayscale images from the CELLO registry were systematically reviewed for dissections in the treated vessel segments by two investigators. Images from 33 patients; 66 pullbacks (1867 IVUS frames in 2 phases), were successfully matched frame-to-frame to evaluate identical segments of the treated vessels in the two phases; post-2 mm Turbo-Elite laser pilot channel creation and post Turbo-Booster laser atherectomy. Dissections were categorized as; (1) intimal, (2) medial, (3) intramural hematoma, and (4) adventitial according to the ACC Clinical Expert Consensus Document classification of dissections. An average of 57 frames was evaluated per pullback, giving a total of 3734 frames (1867 matched for pre-ablation (post channel creation) and post-ablation phases). Treatments with the modified Excimer laser catheters resulted in a significant increase in lumen area of 5.5?±?3.2-mm2 (95% CI 4.3–6.8, p?<?0.0001) and reduction in plaque plus media volume of ?10.6?±?36.0 mm3 (95% CI ?25.8 to 4.6, p?=?0.1619) whilst giving rise to mainly intramural hematoma formations post Turbo-Booster laser treatment in 55% of frames assessed and 24% medial dissections with less than 1% adventitial disruption. The Excimer laser based Turbo-Booster treatment of peripheral artery lesions resulted in significant plaque debulking and increased lumen diameter with negligible degree of adventitial layer injury. 相似文献